We are live on ! Find out more
SC

Stempoint Capital Portfolio holdings

AUM $581M
1-Year Est. Return 373.68%
This Fund
S&P 500
This Quarter Est. Return
+35.11%
1 Year Est. Return
+373.68%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$581M
AUM Growth
+$58.2M
Cap. Flow
-$54.7M
Cap. Flow %
-9.43%
Top 10 Hldgs %
40.99%
Holding
116
New
34
Increased
19
Reduced
30
Closed
32

Top Buys

Rank Stock Value
1
TNGX icon
Tango Therapeutics
TNGX
+$25.3M
2
ERAS icon
Erasca
ERAS
+$19M
3
TYRA icon
Tyra Biosciences
TYRA
+$14.5M
4
TRAX
First Tracks Biotherapeutics
TRAX
+$11.6M
5
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$10.9M

Top Sells

Rank Stock Value
1
SRRK icon
Scholar Rock
SRRK
+$38.5M
2
SNDX icon
Syndax Pharmaceuticals
SNDX
+$28.4M
3
RVMD icon
Revolution Medicines
RVMD
+$17.8M
4
MBX
MBX Biosciences
MBX
+$14.9M
5
IMVT icon
Immunovant
IMVT
+$14.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.23%
2 Miscellaneous 0.45%
3 Financials 0.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IFRX icon
26
InflaRx
IFRX
$323M
$7.23M 1.25%
+3,228,255
New +$6.07M
AMLX icon
27
Amylyx Pharmaceuticals
AMLX
$3.74B
$6.9M 1.19%
384,304
-285,381
-43% -$4.41M
CLDX icon
28
Celldex Therapeutics
CLDX
$3.09B
$6.64M 1.14%
178,412
-75,855
-30% -$2.45M
OVID icon
29
Ovid Therapeutics
OVID
$549M
$6.5M 1.12%
+2,417,283
New +$6.24M
EQ icon
30
Equillium
EQ
$142M
$6.45M 1.11%
+2,016,607
New +$4.83M
DFTX
31
Definium Therapeutics
DFTX
$5.13B
$6.45M 1.11%
137,124
-188,359
-58% -$4.65M
CYTK icon
32
Cytokinetics
CYTK
$10.2B
$6.44M 1.11%
75,603
-53,974
-42% -$3.88M
DMRA
33
Damora Therapeutics
DMRA
$1.71B
$5.62M 0.97%
+216,194
New +$5.24M
IVA
34
Inventiva
IVA
$1.12B
$5.39M 0.93%
+1,426,320
New +$6.85M
IPSC icon
35
Century Therapeutics
IPSC
$380M
$5.26M 0.91%
+2,146,182
New +$4.9M
AURA icon
36
Aura Biosciences
AURA
$775M
$5.07M 0.87%
+714,280
New +$5.11M
EYPT icon
37
EyePoint Inc
EYPT
$389M
$4.84M 0.83%
338,471
-472,293
-58% -$6.32M
ASMB icon
38
Assembly Biosciences
ASMB
$725M
$4.68M 0.81%
170,378
-15,057
-8% -$410K
WHWK
39
Whitehawk Therapeutics
WHWK
$260M
$4.68M 0.81%
1,021,037
+81,668
+9% +$340K
XENE icon
40
Xenon Pharmaceuticals
XENE
$5.83B
$4.59M 0.79%
76,075
-64,680
-46% -$3.59M
QURE icon
41
uniQure
QURE
$3.1B
$4.06M 0.7%
88,115
+10,049
+13% +$263K
CMPS
42
Compass Pathways
CMPS
$1.83B
$4.03M 0.69%
+284,769
New +$2.89M
AVLN
43
Avalyn Pharma
AVLN
$1.6B
$3.88M 0.67%
+118,000
New +$3.41M
MPLT
44
MapLight Therapeutics
MPLT
$614M
$3.83M 0.66%
106,906
+6,906
+7% +$199K
ALMS
45
Alumis Inc
ALMS
$1.46B
$3.82M 0.66%
135,736
-93,830
-41% -$2.18M
AXSM icon
46
Axsome Therapeutics
AXSM
$10.8B
$3.76M 0.65%
+15,375
New +$3.33M
GLUE icon
47
Monte Rosa Therapeutics
GLUE
$1.22B
$3.72M 0.64%
+153,544
New +$2.9M
ACAD icon
48
Acadia Pharmaceuticals
ACAD
$4.83B
$3.62M 0.62%
143,167
-99,399
-41% -$2.19M
SLDB icon
49
Solid Biosciences
SLDB
$1.1B
$3.58M 0.62%
358,780
+163,377
+84% +$1.24M
PSNL icon
50
Personalis
PSNL
$1.8B
$3.32M 0.57%
+247,783
New +$2.02M
1
2
3 4 5

Similar funds

PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
CMA
Cedar Mountain Advisors Lake Oswego, Oregon $581M AUM 18.16% 1-Year Est. Return
RIS
Retirement Income Solutions Ann Arbor, Michigan $581M AUM 19.42% 1-Year Est. Return
GFI
Global Frontier Investments Charleston, South Carolina $581M AUM 8.55% 1-Year Est. Return
CCWM
Correct Capital Wealth Management Clayton, Missouri $580M AUM 16.45% 1-Year Est. Return
MFS
McNamara Financial Services Marshfield, Massachusetts $580M AUM 17.89% 1-Year Est. Return
PWM
Praetorian Wealth Management Carmel, California $580M AUM 19.43% 1-Year Est. Return
CA
Cambridge Advisors Omaha, Nebraska $582M AUM 19.14% 1-Year Est. Return

Stempoint Capital's Q2 2026 Portfolio in Review

As of Q2 2026, Stempoint Capital held 116 positions worth $581M, up 11% from $522M the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Stempoint Capital withdrew a net $54.7M in Q2 2026, closing 32 positions and reducing 30 holdings. Its most notable exit was Syndax Pharmaceuticals, an estimated $28.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Stempoint Capital opened a new position in First Tracks Biotherapeutics worth $12.5M.

  • Stempoint Capital's largest Q2 2026 buy was First Tracks Biotherapeutics: 622,723 shares worth $12.5M.
  • Stempoint Capital added most to Tango Therapeutics in Q2 2026, an estimated $25.3M increase.
  • Stempoint Capital's biggest Q2 2026 reduction was Scholar Rock, cutting an estimated $38.5M.
  • Stempoint Capital fully exited Syndax Pharmaceuticals in Q2 2026, selling an estimated $28.4M.
  • Stempoint Capital's ten largest holdings make up 41% of its $581M portfolio in Q2 2026.
  • Stempoint Capital opened 34 new positions and closed 32 in Q2 2026.
  • Stempoint Capital's portfolio value rose 11% quarter-over-quarter to $581M.

Based on Stempoint Capital's 13F filing for Q2 2026, filed 14 Aug 2026.